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 Abstract
Background and Objective: Desensitization protocols for patients with immediate hypersensitivity reactions (IHSRs) have proven to be 
effective, but they are not widely used in clinical practice because of impracticalities such as high cost, long procedure duration, and a 
lack of trained personnel. We aimed to determine the clinical characteristics of oxaliplatin-induced IHSRs and assess measures to protect 
against these reactions and to validate a new practical desensitization protocol.
Methods: We retrospectively reviewed 2640 cases of oxaliplatin IHSRs in 271 oxaliplatin users and prospectively used a newly designed 
desensitization protocol 32 times in 12 patients with hypersensitivity to platinum-based chemotherapy. The protocol consisted of increases 
in infusion rate every 15 minutes, regardless of the concentration of the chemotherapy agent in the infusion bags.
Results: Of the 271 patients administered oxaliplatin, 45 (16.6%) experienced IHSRs. Of 39 patients who experienced an IHSR but needed 
to continue oxaliplatin, 6 (15.4%) stopped treatment due to the reaction, and 33 (84.6%) continued despite the risk of further reactions. 
The new desensitization protocol was successfully completed in 12 patients (100%), but it was ineffective in 3 patients (all with a negative 
skin prick test), who experienced fever without urticaria.
Conclusions: Many patients who experience oxaliplatin-induced IHSRs are required to stop first-line oxaliplatin-based chemotherapy or to 
continue without desensitization, with the associated risks. Our new desensitization protocol is practical and easy to use in clinical practice.
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 Resumen
Introducción y Objetivos: El protocolo de desensibilización en los pacientes con reacciones de hipersensibilidad inmediata a quimioterápicos 
resulta efectivo, sin embargo no se aplica en muchos hospitales debido a su alto coste, consumo de tiempo y falta de personal entrenado. 
El motivo de este trabajo fue analizar las características clínicas y las medidas habitualmente adoptadas en esta patología y validar un 
nuevo protocolo de desensibilización a oxaliplatino.
Métodos: Para ello revisamos retrospectivamente 2.640 reacciones de hipersensibilidad inmediata a oxaliplatino en 271 pacientes sometidos 
a tratamiento con este quimioterápico. De forma prospectiva, aplicamos un nuevo protocolo de desensibilización 32 veces en 12 pacientes 
con hipersensibilidad inmediata a quimioterapia basada en oxaliplatino. Este nuevo protocolo se realizó con la administración escalonada 
de la concentración determinada cada 15 minutos.
Resultados: En cuanto a los resultados obtenidos, de los 271 pacientes a los que se administró oxaliplatino, 45 (16,6%) presentaron 
reacciones de hipersensibilidad inmediata. De los 39 que necesitaron seguir el tratamiento con oxaliplatino, 6 (15,4%) abandonaron el 
tratamiento y 33 (84,6%) continuaron. El nuevo protocolo de desensibilización se completó en 12 pacientes (100%) si bien tres de ellos 
manifestaron fiebre sin urticaria y una respuesta negativa en la prueba cutánea.
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Introduction
Oxaliplatin, a platinum-containing agent, is a first-line drug 
treatment for colorectal cancer [1]. However, between 12% and 
24% of patients have been reported to experience immediate 
hypersensitivity reactions (IHSRs) to this drug [2-4], and the 
prevalence of reactions is rising at a rate parallel to that of 
oxaliplatin use [5-7]. As oxaliplatin IHSRs usually occur on 
re-exposure, numerous patients discontinue oxaliplatin-based 
chemotherapy. Replacement of oxaliplatin with another agent, 
however, can negatively affect survival. In clinical practice, 
many clinicians continue to use oxaliplatin-containing 
regimens in patients who have experienced reactions. 
Rather than attempting desensitization, however, they use a 
premedication strategy consisting of corticosteroids and/or 
antihistamines. The patient remains at risk of an IHSR, which 
can cause urticaria, angioedema, anaphylaxis, and even death. 
Although many studies have evaluated the predictive 
factors for oxaliplatin-induced IHSRs, the findings remain 
controversial. To date, number of oxaliplatin administrations 
is the only unanimously accepted predictor. It has been widely 
suggested that IHSRs to oxaliplatin occur during the seventh, 
eighth, or ninth infusion [6,8-12], but there have been some 
reports of IHSRs occurring during the third infusion [10,13]. 
To ensure safe administration of oxaliplatin-containing 
regimens, leading institutes have attempted desensitization 
protocols [10,14-17], with almost all studies showing high 
success rates. The most widely used desensitization protocol 
is the classic 12-step protocol described by Castells et al [17], 
in which the infusion rate is doubled every 15 minutes, from 
2 mL/min to 80 mL/min. In this protocol, infusion rates 
vary according to the infusion bags, which contain various 
concentrations of oxaliplatin. Although this protocol is 
known to be highly successful, it has many limitations in 
actual practice. Many hospitals have yet to use the protocol 
because of its high cost, long duration, and lack of trained health 
professionals. More suitable desensitization protocols are needed 
for real practice and as a result, some hospitals have designed 
new protocols [18]. At our hospital, we developed a new protocol 
that is easy and convenient for use in routine practice. It is an 
11-step protocol in which the infusion rate is regularly increased 
from 60 mL/min to 120 mL/min or 240 mL/min, regardless of 
the concentration of oxaliplatin in the infusion bags. We believe 
that this modified protocol is more convenient and will help 
to reduce errors in clinical practice.
We were interested in understanding the clinical 
characteristics and predictors of oxaliplatin IHSRs and 
of analyzing the effectiveness of our new desensitization 
protocol. To this end, we retrospectively reviewed 2640 
cases of oxaliplatin-based chemotherapy in 218 patients to 
determine the clinical characteristics of oxaliplatin-induced 
IHSRs in clinical practice and assess measures used to protect 
against these reactions. We then prospectively used the newly 
designed desensitization protocol in 32 cases of platinum-based 
chemotherapy IHSR in 12 patients to test its validity. 
Methods
Patients 
We enrolled 271 patients who were scheduled to receive an 
oxaliplatin-containing chemotherapy regimen upon admission 
to the Severance Hospital in Korea between March 1, 2013 
and March 31, 2013. We retrospectively reviewed the patients’ 
medical records and analyzed 2640 cases of oxaliplatin-
induced IHSRs in these 271 patients. All the patients had 
been pretreated with 8 mg of dexamethasone and 4 mg of 
chlorpheniramine maleate administered intravenously 30 
minutes before oxaliplatin infusion.
The desensitization protocol was used in 12 patients 
between May 1, 2014 and May 31, 2015. All 12 patients 
had experienced IHSRs to platinum-based chemotherapy 
(oxaliplatin or cisplatin), and based on the oncologist’s opinion, 
they required additional platinum-based chemotherapy to 
treat their underlying disease. In cases where the patient had 
received a platinum-based chemotherapy regimen differing in 
dosage from the original regimen, we counted the number of 
cycles from the first platinum-based regimen. 
Skin Test Protocol
The 12 patients who received platinum-based chemotherapy 
using the newly designed desensitization protocol underwent 
a skin test 30 minutes before the start of the protocol. We 
intradermally injected the platinum-based chemotherapy 
agent into the middle portion of the patient’s forearm. The 
concentrations and amounts of oxaliplatin and cisplatin were 
5 mg/mL and 0.03 mL and 1 mg/mL and 0.03 mL, respectively. 
Results were read 15 minutes after injection. Positive reactions 
were defined as a wheal size of 3 mm or greater.
New Desensitization Protocol
We designed a practical new 11-step protocol in which 
the amount of oxaliplatin infused is similar to that used in the 
classic desensitization protocol [17]. Four bags containing 
different concentrations of oxaliplatin (1:1, 1:10, 1:100, 
1:1000) were prepared as per the instruction manual. We 
first prepared one 500-mL bag containing 1:1 crude solution 
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Conclusiones: En conclusión, una proporción importante de pacientes que sufren reacciones de hipersensibilidad a oxaliplatino interrumpen 
el tratamiento o lo mantienen sin ser sometidos a protocolos de desensibilización. El protocolo de desensibilización que proponemos en 
este estudio es fácil y muestra resultados satisfactorios en la práctica clínica.
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We used a DI-2000 volumetric infusion pump (DAIWHA 
Corp., LTD.) to ensure accurate infusion rates and volumes. 
Infusion rate and volume can be established by inputting a 
number into the blank spaces on the device. When the assigned 
target volume is reached, an alarm sounds. For example, we 
input 60 into the space for rate adjustment and 15 into the space 
for volume adjustment before beginning to infuse solution A. 
Accordingly, this solution is infused at a rate of 60 mL/h until 
the infused volume of 15 mL is reached at 15 minutes. When 
the alarm sounds, we input 120 and 30 into the blank spaces for 
rate and volume, respectively. The solution is then infused at 
120 mL/h for 15 minutes until a volume of 30 mL is reached. 
Following this procedure, four bags were regularly infused at 
an exact rate and volume.
IHSRs
IHSRs were graded using the Common Terminology 
Criteria for Adverse Events (CTCAE) version 4.0. Grade 1 
reactions involve transient flushing or rash and drug-related 
fever of under 38°C (<100.4°F) and do not require intervention; 
grade 2 reactions require intervention or interruption of 
infusion, prompt response for symptomatic treatment, and 
prophylactic medications for 24 hours or less; grade 3 reactions 
involve prolonged IHSRs, with recurrence of symptoms 
following initial improvement and hospitalization for clinical 
sequelae; grade 4 reactions have life-threatening consequences 
and require urgent intervention; and grade 5 reactions result 
in death [19]. We defined a mild reaction as grades 1–2 and a 
severe reaction as grades 3–5.
Ethics
This study was approved by the institutional review board 
at the Severance Hospital, Yonsei University Health System 
(approval number: 4-2014-0422). Before participation in 
the study, written informed consent was obtained from all 
participants.
Statistical Analysis
We determined ORs using logistic regression analysis 
in SPSS version 18.0. We first conducted univariate logistic 
regression analysis, followed by multiple logistic regression 
analysis using variables with a significant OR in the univariate 
analysis. Cross-correlation analysis was performed using 
χ2 tests to analyze the correlation between the number of 
chemotherapy cycles and IHSRs. We considered a P value 
of less than .05 to be significant. Mean values are expressed 
as mean (SD).
Results
Baseline Characteristics and Clinical Manifestations 
of Oxaliplatin-Induced IHSRs in 271 Patients
There were slightly more women (56.3%) in the sample. 
The mean (SD) age and BSA were 58.1 (11.1) years and 1.6 
(0.17) m2. The most common underlying disease was colorectal 
(D solution) and three 100-mL bags containing 5% dextrose 
solution (A–C solutions). The D solution is used when patients 
receive platinum-based chemotherapy from the beginning of 
the chemotherapy regimen. The concentration of oxaliplatin 
is usually calculated using the patient’s body surface area 
(BSA). We infused 10 mL of D solution into one 100-mL 
bag (C solution), at which point the C solution was diluted 
at a ratio of 1:10 of the D solution. We infused 10 mL of C 
solution into another 100-mL bag (B solution), and the B 
solution was diluted at a ratio of 1:100 of the D solution. 
Finally, the A solution (1:1000) was created by infusing 10 mL 
of the B solution into another 100-mL solution (Figure 1). We 
infused the 4 bags by order of concentration (A, B, C, and D, 
respectively). Rate of infusion was adjusted approximately 
every 15 minutes, from an initial rate of 60 mL/h to 120 mL/h 
or 240 mL/h. The last step of the classic 12-step protocol was 
omitted because the literature shows this step to be associated 
with an increased risk of IHSRs [17]. The final step of the 
newly designed 11-step protocol, which lasted 237.5 minutes 
at the 120 mL/h infusion rate, was carefully performed and 
monitored by an allergist (Table 1).
Table 1. New Practical Oxaliplatin Desensitization Protocol  
Step Solution Rate Time  Volume Fold 
  (mL/h)  (min) Infused per Increase 
    Step (mL) per Step
1 A solution (1:1000) 60 15 15 -
2  120 15 30 2
3  240 16.25 65 2
4 B solution (1:100) 60 15 15 2.5
5  120 15 30 2
6  240 13.75 55 2
7 C solution (1:10) 60 15 15 2.5
8  120 15 30 2
9  240 13.75 55 2
10 D solution 
 (1:1 crude solution) 60 15 15 2.5
11  120 237.5 475 2
Total  383.25 800
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cutaneous symptoms, including pruritus, rash, and urticaria 
(46.7%). Respiratory symptoms (chest tightness and dyspnea) 
and general symptoms (fever and myalgia) were also common 
(42.2% each). Cardiovascular symptoms, rhinorrhea, and 
neurologic symptoms were rare (Table 2).
IHSRs 
Figure 2 shows a flowchart of IHSRs. Of the 45 patients 
who experienced these reactions, 34 patients, 9 patients, and 
2 patients experienced grade 1, 2, and 3 reactions during their 
first IHSR, respectively. Thirty-two of the 34 patients who 
experienced a grade 1 reaction were re-exposed to oxaliplatin. 
Of these, 19 patients experienced a second grade 1 reaction 
during subsequent chemotherapy and 1 patient experienced 
a grade 2 reaction. Seven of the 9 patients who experienced 
a grade 2 reaction during the first IHSR were re-exposed. 
Three experienced another grade 2 reaction during additional 
chemotherapy. The 2 patients who experienced a grade 3 
reaction during the first IHSR stopped chemotherapy as a direct 
result. Consequently, the recurrence rate of IHSRs was 59.0% 
(23 patients with IHSR recurrence/39 patients re-exposed to 
oxaliplatin).
Of the 19 patients who experienced a grade 1 IHSR during 
re-exposure, 7 experienced at least one other grade 1 reaction, 
1 experienced a grade 2 reaction, and 1 experienced a grade 
3 reaction during subsequent chemotherapy. Of the 4 patients 
who experienced a grade 2 IHSR during re-exposure, 1 patient 
experienced another reaction of equal severity and 1 stopped 
chemotherapy due to recurrent IHSRs. Of the 10 patients who 
experienced a third oxaliplatin IHSR, 2 experienced additional 
IHSRs during further chemotherapy. These 2 patients and an 
additional patient who experienced a grade 3 reaction during 
the third IHSR stopped chemotherapy. Of the 39 patients who 
experienced an IHSR and were required to have additional 
chemotherapy, 6 patients did not continue the chemotherapy 
Table 2. Baseline Characteristics and Clinical Manifestations  
 Patients (n=271) No. (%)
Sex Male 118 (43.7) 
 Female 152 (56.3)
Diagnosis Colorectal cancer 176 (65.2) 
 Stomach cancer 67 (24.8) 
 Pancreatic cancer 17 (6.3) 
 Ampulla of Vater cancer 6 (2.2) 
 Appendiceal cancer 2 (0.7) 
 Duodenal cancer 1 (0.4) 
 Primary unknown cancer 1 (0.4)
Chemotherapy FOLFOXa 225 (83.3) 
regimen Xeloxb 45 (16.7)
Clinical Cutaneous 21 (46.7) 
manifestations Respiratory 19 (42.2) 
 General 19 (42.2) 
 Cardiovascular 2 (4.4) 
 Rhinorrhea 2 (4.4) 
 Neurologic 1 (2.2)
aFOLFOX: oxaliplatin 85 mg/m2 intravenous infusion (IVF), fluorouracil 
400 mg/m2 intravenous bolus, fluorouracil 2400 mg/m2 IVF, leucovorin 
200 mg/m2 IVF
bXelox: oxaliplatin 130 mg/m2 IVF, capecitabine 1500 mg/m2 orally 
divided by 2 daily doses for 14 days.




























cancer (65.2%), followed by stomach cancer (24.8%), and 
pancreatic cancer (6.3%). The mean infused chemotherapy 
dose, which was adjusted to BSA, was 91.4 (18.4) mg/m2. 
The mean number of infusion cycles was 9.8 (4.3). Most 
individuals who received oxaliplatin were being treated with 
FOLFOX chemotherapy.
Oxaliplatin-induced IHSRs occurred in 45 (16.7%) of the 
271 patients. The most common clinical manifestations were 
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regimen after this first reaction (discontinuation rate due to 
oxaliplatin IHSR, 15.4%). However, the remaining 33 patients 
(84.6%) continued chemotherapy, regardless of the high risk of 
urticaria, angioedema, or anaphylaxis due to IHSR recurrence. 
ORs for IHSRs Induced by Oxaliplatin
Based on the logistic regression analysis, type of 
chemotherapy regimen (P=.281) and total number of cycles 
administered (P=.762) were not risk factors for oxaliplatin-
induced IHSRs. Significant ORs, however, were observed 
for sex, BSA, current cycle of chemotherapy, infusion 
dose (mg/m2), infusion amount (mg), and total accumulated 
amount (mg). The adjusted ORs for these variables, however, 
were not statistically significant (Table 3). Nonetheless, 
the cross-correlation analysis showed that number of 
chemotherapy cycles was significantly correlated with the 
occurrence of IHSRs (P<.001).
Chemotherapy Cycle at Moment of First IHSR
IHSRs occurred approximately during the third cycle 
and after the sixth cycle (Figure 3). Of the 5 patients who 
experienced their first IHSR during the third cycle, 2 
patients developed fever, and the others experienced throat 
tightness, rash, and urticaria. After the sixth cycle, the patients 
experienced, to diverse extents, fever, urticaria, pruritus, 
dyspnea, and anaphylaxis (Table 4).
Clinical Characteristics of Patients Who Underwent 
Desensitization
We used our new desensitization protocol 32 times in 12 
prospectively enrolled patients who had experienced an IHSR 
to platinum-based chemotherapy. Their mean (SD) age was 51.6 
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Figure 3. Number of chemotherapy cycles when first immediate 
hypersensitivity reaction (IHSR) to oxaliplatin occurred.
Table 3. ORs for Immediate Hypersensitivity Reactions Induced by Oxaliplatin  
 OR (95% CI) P Value Adjusted OR (95% CI) P Value
Sex (female) 0.592 (0.367-0.956) .032 0.713 (0.393-1.292) .265
Body surface area (m2) 5.651 (1.479-21.585) .011 0.050 (0.000-24.964) .345
Relevant cycle of chemotherapy 1.132 (1.085-1.181) <.001 0.996 (0.805-1.233) .970
Infusion dose (mg/m2) 0.972 (0.958-0.986) <.001 0.895 (0.783-1.023) .104
Infusion amount (mg) 0.991 (0.983-0.998) .012 1.050 (0.972-1.135) .215
Total accumulated amount (mg) 1.001 (1.000-1.001) <.001 1.001 (0.999-1.002) .276
Table 4. Symptoms of IHSRs According to Cycle During Which the First 
IHSR Occurred  
Cycle When  Symptom Cycle When Symptom 
First IHSR  First IHSR  
Occurred  Occurred
1 Throat tightness 9 Fever
2 Pruritus 9 Fever
3 Fever 9 Urticaria
3 Fever 9 Urticaria
3 Throat tightness 9 Urticaria
3 Rash 10 Fever
3 Urticaria 10 Fever
4 Chest tightness 10 Fever
5 Rhinorrhea 10 Fever
6 Hypertension 10 Rhinorrhea
6 Fever 10 Pruritus
6 Urticaria 10 Urticaria
6 Urticaria 10 Urticaria
7 Fever 11 Fever
7 Pruritus 11 Fever
7 Pruritus 11 Pruritus
7 Urticaria 11 Dyspnea
7 Anaphylaxis 12 Fever
8 Fever 12 Fever
8 Fever 12 Rash 
8 Pruritus 13 Fever
8 Rash 15 Urticaria
8 Urticaria
Abbreviation: IHSR, immediate hypersensitivity reaction.
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was 6.5 (6.7), and the mean number of cycles before the patients 
first underwent desensitization was 9.4 (7.1). Most patients had 
colorectal cancer (42.7%) or stomach cancer (42.7%). One of 
the patients with stomach cancer and one with cervical cancer 
received cisplatin-based chemotherapy, and the rest received 
oxaliplatin-based chemotherapy. Half of the patients had 
experienced severe IHSRs, including anaphylactic shock. The 
most common type of IHSR consisted of general symptoms, such 
as fever, hypertension, and anaphylaxis. Many of the patients also 
experienced cutaneous symptoms (pruritus, urticaria, and rash, 
50.0%) and respiratory symptoms (chest tightness, wheezing, 
dyspnea, 42.7%), and some patients experienced tachycardia, 
nausea, and a tingling sensation (Table 5).
Results of Intradermal Skin Tests and Responses to 
the Newly Designed Desensitization Protocol
All patients successfully underwent the newly 
designed desensitization protocol including the full dose of 
chemotherapy. There were no complications or deaths. Almost 
all of the patients (87.5%) experienced either a mild adverse 
reaction or no reaction. Mild reactions recurred in 42.8% of 
all cases. All 9 patients who had a mild reaction or no reaction 
showed positive results on the skin test. Of the 5 patients who 
experienced a mild reaction, 3 experienced symptoms during 
the 11th step, which consisted of a 1:1 concentration of the 
D solution at 120 mL/h. One patient experienced symptoms 
during the 10th step, which consisted of a 1:1 concentration 
of the D solution at 60 mL/h. Only 1 patient experienced 
symptoms immediately after the skin test. However, after 
treatment with dexamethasone and pheniramine, their 
symptoms were relieved. Patient 9 experienced urticaria, 
chest tightness, nausea, and dizziness immediately after the 
skin test. During desensitization, patient 9 developed some 
breakthrough symptoms; treatment with dexamethasone 
and pheniramine, followed by a 30-minute pause, helped to 
improve tolerability and allowed the desensitization protocol 
to be completed (Table 6).
Only 4 of the IHSRs (12.5%), in 3 patients, were severe. 
While the patients had no urticaria or pruritus, they did 
experience fever or hypertension with a mild rash and flushing. 
The fever and/or hypertension occurred immediately after 
oxaliplatin infusion, and the symptoms could only be explained 
by this infusion. The 3 patients showed negative results on 
the skin test. They experienced their first IHSR during the 
first to third cycle of chemotherapy, and chose not to undergo 
additional steps of the desensitization protocol because they felt 
that it was not effective. They finally switched to a platinum-
free chemotherapy regimen (Table 6).
Discussion
Many studies have investigated the predictive factors for IHSR. 
In Japan, one study revealed that serum lactate dehydrogenase 
(LDH) levels at the beginning of chemotherapy might predict 
IHSRs to oxaliplatin [20], and a Korean study suggested that 
the amount of dexamethasone used as premedication could 
predict IHSRs [21]. Further studies, however, are needed to 
confirm the reliability of these factors. In our study, LDH was 
not routinely measured at the start of chemotherapy. All the 
individuals received premedication including dexamethasone and 
chlorpheniramine immediately before the infusion of oxaliplatin. 
Our study did not find that any of these newly reported factors 
were predictive of oxaliplatin IHSR, supporting the findings of 
other studies [6]. Coinciding with many previous studies, in our 
series, only number of chemotherapy cycles was significantly 
correlated with the occurrence of IHSRs.
First IHSRs to oxaliplatin tend to occur during the seventh 
to ninth infusion [6,8-12], although recent studies have shown 
that they can occur earlier [10,13]. In our study, we observed 
2 peaks of occurrence for the first IHSR: one around the third 
cycle and another around the sixth cycle. These data suggest 
that a significant portion of oxaliplatin IHSRs can occur earlier 
than previously reported. We analyzed the symptoms of IHSRs 
according to the cycle administered, but found no significant 
differences between early (around the third cycle) and late 
(seventh-eight cycles) occurrences. 
IHSRs are generally divided into 2 types: true allergic IHSRs 
that usually involve IgE-mediated (type 1) hypersensitivity, and 
pseudoallergic or idiosyncratic IHSRs that are not associated 
with IgE. Some drugs, such as radiocontrast media, are 
considered to result in both types of IHSR [22]. Skin tests are 
a diagnostic tool for IgE-mediated IHSRs. A negative skin 
test in certain IHSR patients might suggest that IHSRs are 
non-IgE-mediated reactions. However, the sensitivity rates 
of skin tests to oxaliplatin vary from 26% to 100% [9,23,24]. 
Furthermore, the ImmunoCAP system, which measures 
specific IgE in oxaliplatin-reactive patients, has a sensitivity 
of 38% to 54% [23]. In our study, the rate of positive skin 
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Table 5. Clinical Characteristics of 12 Patients Enrolled in Prospective 
Desensitization Study  
Variables  Mean (SD)
Age, y  51.6 (8.4)
Cycle when first IHSR occurred 6.5 (6.7)
Cycle when desensitization protocol  
was first administered  9.4 (7.1)
Variables  No. (%)  
  of Patients
Underlying disease Colorectal cancer 5 (42.7) 
 Stomach cancer 5 (42.7) 
 Gallbladder cancer 1 (8.3) 
 Cervical cancer 1 (8.3)
Type of chemotherapy Oxaliplatin 10 (83.3) 
 Cisplatin 2 (16.7)
Grade of IHSR Mild 6 (50.0) 
 Severe 6 (50.0)
Type of IHSR General 8 (66.7) 
 Cutaneous 6 (50.0) 
 Respiratory 5 (42.7) 
 Cardiologic 2 (16.7) 
 Gastrointestinal 1 (8.3) 
 Neurologic 1 (8.3)
Total  12 (100.0)
Abbreviation: IHSR, immediate hypersensitivity reaction.
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tests in the 12 patients who underwent the desensitization 
protocol was 65%, but the nonresponders to this protocol 
had negative skin test responses, suggesting the involvement 
of a non-IgE mediated mechanism. There are 2 likely types 
of mechanisms in oxaliplatin-induced IHSRs: IgE-mediated 
and non-IgE-mediated. Negative skin test results may indicate 
non-IgE-mediated IHSRs and consequently a lower likelihood 
of the desensitization protocol being effective. Further studies 
with larger samples are needed to confirm the validity of skin 
tests for predicting the success of this desensitization protocol. 
We did not evaluate the level of specific IgE to oxaliplatin. 
For ELISA analysis, conjugation of oxaliplatin with a carrier 
protein is needed, but the in vitro conjugation process is not 
easy due to the chemical structure of oxaliplatin. 
The prevalence of IHSRs to oxaliplatin is so high that many 
patients decide to stop oxaliplatin-based chemotherapy and 
switch to another, less effective, agent. Desensitization is an 
ideal strategy for maintaining the safety and effectiveness of 
oxaliplatin-based chemotherapy. From a practical standpoint, 
the well-known classic desensitization protocol has several 
limitations. First, the preparation of solutions is impractical, 
and the calculation of formulas for preparing the 3-bag solution 
are complicated and time-consuming. These challenges 
can cause errors during solution preparation. Second, the 
recommended infusion rate and volume for 15 minutes are 
also impractical. Based on the classic desensitization protocol, 
0.5 mL of the first solution should be infused for 15 minutes, 
but this tiny volume can remain in the line or syringe needle for 
this time, making it impossible to ensure that the exact amount 
of solution is infused into the patient over the established 15 
minutes. Third, the infusion rate varies from 2 mL/h to 80 mL/h 
according to the solution concentration. Such variations might 
cause confusion among health professionals and lead to errors. 
The newly designed desensitization protocol is suitable for 
real clinical practice. Formula calculations are not difficult, 
and the only reagent that needs to be prepared is the crude 
174
Table 6. Results of Intradermal Skin Test and Responses to the Newly Designed Oxaliplatin Desensitization Protocol
Patient Type of  Cycle When Main Clinical No. of Cycle Skin Results Protocol Step 
 Chemotherapy First IHSR  Manifestation Desensitizations  Test  When First 
  Occurred      IHSR Occurred
1 Oxaliplatin 11 Anaphylactic shock 1 13 + Mild reaction Step 11  
    2 14 + No reaction  
    3 15 + No reaction  
    4 16 + No reaction 
2 Cisplatin 25 Anaphylactic shock 1 26 + Mild reaction Step 11  
    2 27 + No reaction  
    3 28 + No reaction 
3 Oxaliplatin 9 Anaphylaxis 1 12 + No reaction 
4 Oxaliplatin 3 Anaphylaxis 1 3 + No reaction  
    2 4 + No reaction  
    3 5 + No reaction  
    4 6 + No reaction 
5 Oxaliplatin 6 Fever, urticaria 1 12 + Mild reaction Step 11  
    2 13 + Mild reaction Step 11  
    3 14 + Mild reaction Step 11  
    4 15 + Mild reaction Step 11 
6 Oxaliplatin 7 Fever 1 11 + No reaction  
    2 12 + No reaction 
7 Oxaliplatin 1 Fever 1 7 + No reaction  
    2 8 + No reaction 
8 Oxaliplatin 7 Fever, hypertension, urticaria 1 16 + Mild reaction Step 10 
    2 17 + Mild reaction Step 10 
    3 18 + Mild reaction Step 10 
    4 19 + Mild reaction Step 10 
    5 20 + Mild reaction Step 11
9 Cisplatin 2 Anaphylactic shock 1 3 + Mild reaction Skin test 
    2 4 + Mild reaction Skin test 
    3 5 + Mild reaction Skin test
10 Oxaliplatin 2 Hypertension, fever 1 4 - Severe reaction Step 11
11 Oxaliplatin 1 Fever 1 3 - Severe reaction Step 11 
    2 4 - Severe reaction Step 11
12 Oxaliplatin 3 Fever 1 4 - Severe reaction Step 10
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solution, which is the solution typically used in the standard 
cycle. Using another three 100-mL bags and syringes, it is 
easy to prepare solutions containing 1:10, 1:100, and 1:1000 
concentrations of oxaliplatin. Once the bags are prepared, 
health professionals can infuse the solution using a volumetric 
infusion pump, which automatically adjusts infusion rate and 
volume. Nursing staff can simply input the established rates 
of 60 mL/h to 120 mL/h and 240 mL/h, in that order, into the 
blank space for infusion rate, and then add the established 
volumes of 15 mL and 30 mL. The last number for infusion 
volume can be left empty, meaning that all the solution will 
be infused. If the machine reaches the target volume or infuses 
to the end, an alarm will sound. After infusion of solution 
A, solution B should be infused, in the same order as above, 
from 60 mL/h to 120 mL/h and 240 mL/h. Solutions C and D 
are then infused, also in the same order. Note that solution D 
should not be infused at 240 mL/h. The maximum infusion 
rate for this solution is 120 mL/h, which is about half of the 
normal infusion rate of the original FOLFOX regimen in 
nonsensitized patients. 
This new protocol can be used easily and safely in routine 
clinical practice. It is not only feasible but also reduces the 
potential for medication errors. The success rate of this new 
protocol was high, and it was safely administered to all patients. 
Furthermore, there were no errors during its use in 7 patients. 
The protocol, however, has yet to be applied on a larger scale. 
Therefore, large-scale studies should be conducted to evaluate 
the efficacy and safety of this new protocol.
A considerable number of patients experience IHSRs to 
oxaliplatin, and the decision whether or not to continue with 
what is an effective regimen poses a dilemma. Many hospitals 
hesitate to use the classic desensitization protocol because of 
the duration and cost of the procedure and a lack of health 
professionals trained in its use. We suggest that this new 
practical desensitization protocol will prove useful to patients 
with oxaliplatin-induced IHSRs in real clinical practice. 
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